SCHEMBL4276139

SCHEMBL4276139

C=C(C)OC(=O)Nc1cc(C2CCCC2)no1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.46
MAPK14 Q16539 1/20 0.46
BRAF P15056 4/20 0.42
RAF1 P04049 3/20 0.42
PSMB8 P28062 1/20 0.40
PSMB9 P28065 1/20 0.40
PSMB5 P28074 1/20 0.40
RPS6KA2 Q15349 2/20 0.39
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
EGFR P00533 1/20 0.38
NTRK1 P04629 1/20 0.38
INSR P06213 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CDK1 P06493 1/20 0.38
CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16254888 0.82 MAPK14 (0.52) CNR2MAPK14BRAFRAF1PSMB8
SCHEMBL16254942 0.81 MAPK14 (0.51) CNR2MAPK14BRAFRAF1PSMB8
SCHEMBL15461382 0.76 MAPK14 (0.48) CNR2MAPK14BRAFRAF1PSMB8
SCHEMBL1015843 0.76 MAPK14 (0.50) CNR2MAPK14BRAFRAF1RPS6KA2
SCHEMBL26790004 0.76 MAPK14 (0.52) CNR2MAPK14BRAFRAF1PSMB8
SCHEMBL16253026 0.76 MAPK14 (0.49) CNR2MAPK14BRAFRAF1PSMB8
SCHEMBL11966204 0.75 MAPK14 (0.49) CNR2MAPK14BRAFRAF1RPS6KA2
SCHEMBL11966197 0.73 MAPK14 (0.53) CNR2MAPK14BRAFRAF1RPS6KA2
SCHEMBL5067070 0.72 EPHX2 (0.46) CNR2MAPK14BRAFRAF1RPS6KA2
SCHEMBL13391769 0.71 MAPK14 (0.44) CNR2MAPK14BRAFRAF1RPS6KA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 CNR2 3438/4885MAPK14 240/4885BRAF 1/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 CNR2 3438/4885MAPK14 240/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.